Cardiol Therapeutics (TSE:CRDL) Shares Down 14.6% - Here's Why

Shares of Cardiol Therapeutics Inc. (TSE:CRDL - Get Free Report) were down 14.6% during trading on Monday . The company traded as low as C$1.24 and last traded at C$1.29. Approximately 551,069 shares traded hands during mid-day trading, an increase of 406% from the average daily volume of 108,983 shares. The stock had previously closed at C$1.51.Get Cardiol Therapeutics alerts:Cardiol Therapeutics Stock PerformanceThe firm's 50-day simple moving average is C$1.50 and its two-hundred day simple moving average is C$1.65. The company has a current ratio of 2.49, a quick ratio of 6.84 and a debt-to-equity ratio of 1.59. The company has a market cap of C$129.00 million, a PE ratio of -3.15 and a beta of 1.31. Cardiol Therapeutics (TSE:CRDL - Get Free Report) last released its earnings results on Thursday, November 13th. The company reported C($0.12) earnings per share (EPS) for the quarter. As a group, research analysts anticipate that Cardiol Therapeutics Inc. will post -0.49 earnings per share for the current fiscal year. About Cardiol Therapeutics (Get Free Report)Cardiol Therapeutics Inc NASDAQ: CRDL TSX: CRDL is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease.Read MoreFive stocks we like better than Cardiol TherapeuticsComparing and Trading High PE Ratio StocksCongress Beat the Market Again—Here Are the 3 Stocks They BoughtThe Risks of Owning BondsGo on a Shopping Spree With 3 Top Retail ETFsRussell 2000 Index, How Investors Use it For Profitable TradingIf D-Wave Is Too Risky, Consider These 3 Quantum ETFs for DiversificationThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Cardiol Therapeutics Right Now?Before you consider Cardiol Therapeutics, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.While Cardiol Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here